The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure

Division of Cardiology, the Wallenberg Laboratory for Cardiovascular Research, University Hospital, Goteborg, Sweden.

OBJECTIVES: The aim of the present study was to investigate the association between the homozygous DD (deletion) genotype of the angiotensin-converting enzyme gene and survival and cardiac function in patients with idiopathic congestive heart failure. BACKGROUND: The DD genotype gene is a linkage marker for an etiologic mutation at or near the angiotensin-converting enzyme gene and has been associated with increased risk for the development of coronary artery disease, left ventricular hypertrophy and left ventricular dilation after myocardial infarction. We investigated the association between this angiotensin-converting enzyme genotype and mortality in a population-based cohort of patients with idiopathic congestive heart failure. METHODS: The genotype was determined in 193 patients recruited from a large unselected population of patients with congestive heart failure (n = 2,711). The patients were studied with echocardiography, and survival data were obtained after 5 years of follow-up. A control group from the general population (n = 77) was studied by a similar procedure. RESULTS: The frequency of the D allele was not significantly different in the study and control groups (0.57 vs 0.56, p = NS). Long-term survival was significantly worse in the patients with the DD genotype than in the remaining patients (5-year survival rate 49% vs. 72%, p = 0.0011 as assessed by log rank test). The independent importance of the DD genotype for prognosis was verified by a multivariate Cox proportional hazards analysis, by which the odds ratio for mortality and the DD genotype was 1.69 (95% confidence interval 1.01 to 2.82). The only significant difference in cardiac function data between the two groups was an increase in left ventricular mass index in the DD group (153 +/- 57 vs 134 +/- 44 g/m2, p = 0.019). CONCLUSIONS: Angiotensin-converting enzyme gene DD polymorphism was associated with poorer survival and an increase in left ventricular mass in patients with idiopathic heart failure. The results suggest a possible pathophysiologic pathway between angiotensin-converting enzyme gene polymorphism, angiotensin-converting enzyme activity, myocardial hypertrophy and survival. Therefore, the DD genotype may be a marker of poor prognosis in patients with congestive heart failure.

This article has been cited by other articles:

				K. D. Aaronson and J. Cowger Heart Failure Prognostic Models: Why Bother? Circ Heart Fail, January 1, 2012; 5(1): 6 - 9. [Full Text] [PDF]

				T. P. Cappola and G. W. Dorn II Clinical Considerations of Heritable Factors in Common Heart Failure Circ Cardiovasc Genet, December 1, 2011; 4(6): 701 - 709. [Full Text] [PDF]

				G. W. Dorn II The Genomic Architecture of Sporadic Heart Failure Circ. Res., May 13, 2011; 108(10): 1270 - 1283. [Abstract] [Full Text] [PDF]

				D. M. McNamara and B. London GWAS Applied to Heart Failure: Bigger Will Be Better ... Eventually Circ Cardiovasc Genet, June 1, 2010; 3(3): 226 - 228. [Full Text] [PDF]

				P. M. Kirshbom, W. T. Mahle, R. W. Joyner, T. Leong, M. Wilson, B. E. Kogon, K. R. Kanter, and M. M. Bouzyk The endothelin-1 G5665T polymorphism impacts transplant-free survival for single ventricle patients J. Thorac. Cardiovasc. Surg., July 1, 2008; 136(1): 117 - 122. [Abstract] [Full Text] [PDF]

				G. S. Ginsburg, S. H. Shah, and J. J. McCarthy Taking Cardiovascular Genetic Association Studies to the Next Level J. Am. Coll. Cardiol., September 4, 2007; 50(10): 930 - 932. [Abstract] [Full Text] [PDF]

				Chapter 1: Introduction European Journal of Cardiovascular Prevention & Rehabilitation, September 1, 2007; 14(2_suppl): S2 - S113. [Full Text] [PDF]

				P. Richard, E. Villard, P. Charron, and R. Isnard The Genetic Bases of Cardiomyopathies J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A79 - A89. [Abstract] [Full Text] [PDF]

				L. Wojnowski, B. Kulle, M. Schirmer, G. Schluter, A. Schmidt, A. Rosenberger, S. Vonhof, H. Bickeboller, M. R. Toliat, E.-K. Suk, et al. NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity Circulation, December 13, 2005; 112(24): 3754 - 3762. [Abstract] [Full Text] [PDF]

				P. de Groote, N. Lamblin, N. Helbecque, F. Mouquet, E. Mc Fadden, X. Hermant, P. Amouyel, J. Dallongeville, and C. Bauters The impact of beta-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure Eur J Heart Fail, October 1, 2005; 7(6): 966 - 973. [Abstract] [Full Text] [PDF]

				D. M. McNamara, R. Holubkov, L. Postava, K. Janosko, G. A. MacGowan, M. Mathier, S. Murali, A. M. Feldman, and B. London Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure J. Am. Coll. Cardiol., November 16, 2004; 44(10): 2019 - 2026. [Abstract] [Full Text] [PDF]

				I. Cascorbi, M. Paul, and H. K. Kroemer Pharmacogenomics of heart failure - focus on drug disposition and action Cardiovasc Res, October 1, 2004; 64(1): 32 - 39. [Abstract] [Full Text] [PDF]

				A. M. Feldman The emerging role of pharmacogenomics in the treatment of patients with heart failure Ann. Thorac. Surg., December 1, 2003; 76(6): S2246 - S2253. [Full Text] [PDF]

				P. Le Corvoisier, H.-Y. Park, K. M. Carlson, D. A. Marchuk, and H. A. Rockman Multiple quantitative trait loci modify the heart failure phenotype in murine cardiomyopathy Hum. Mol. Genet., December 1, 2003; 12(23): 3097 - 3107. [Abstract] [Full Text] [PDF]

				G. De Backer (Chairpers, E. Ambrosionie, K. Borch-Johnsen, C. Brotons, R. Cifkova, J. Dallongeville, S. Ebrahim, O. Faergeman, I. Graham, G. Mancia, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts) European Journal of Cardiovascular Prevention & Rehabilitation, December 1, 2003; 10(1_suppl): S1 - S78. [Abstract] [Full Text] [PDF]

				P. A. Doevendans Genetic Polymorphisms and Cardiac Failure Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 23 - 29. [PDF]

				M.R. Abraham, L. J. Olson, M. J. Joyner, S. T. Turner, K. C. Beck, and B. D. Johnson Angiotensin-Converting Enzyme Genotype Modulates Pulmonary Function and Exercise Capacity in Treated Patients With Congestive Stable Heart Failure Circulation, October 1, 2002; 106(14): 1794 - 1799. [Abstract] [Full Text] [PDF]

				A. D. Tiago, D. Badenhorst, D. Skudicky, A. J. Woodiwiss, G. P. Candy, R. Brooksbank, K. Sliwa, P. Sareli, and G. R. Norton An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy Cardiovasc Res, June 1, 2002; 54(3): 584 - 589. [Abstract] [Full Text] [PDF]

				N. Lapointe and J.-L. Rouleau Activation of vascular tissue angiotensin-converting enzyme (ACE) in heart failure: Effects of ACE inhibitors J. Am. Coll. Cardiol., March 6, 2002; 39(5): 776 - 779. [Full Text] [PDF]

				S. Fava, J. Azzopardi, S. Ellard, and A. T. Hattersley ACE Gene Polymorphism as a Prognostic Indicator in Patients With Type 2 Diabetes and Established Renal Disease Diabetes Care, December 1, 2001; 24(12): 2115 - 2120. [Abstract] [Full Text] [PDF]

				M. Cicoira, L. Zanolla, A. Rossi, G. Golia, L. Franceschini, G. Cabrini, A. Bonizzato, M. Graziani, S. D. Anker, A. J. S. Coats, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1808 - 1812. [Abstract] [Full Text] [PDF]

				D. M. McNamara, R. Holubkov, K. Janosko, A. Palmer, J. J. Wang, G. A. MacGowan, S. Murali, W. D. Rosenblum, B. London, and A. M. Feldman Pharmacogenetic Interactions Between {beta}-Blocker Therapy and the Angiotensin-Converting Enzyme Deletion Polymorphism in Patients With Congestive Heart Failure Circulation, March 27, 2001; 103(12): 1644 - 1648. [Abstract] [Full Text] [PDF]

				G. J. Perry, T. Mori, C.-C. Wei, X. Y. Xu, Y.-F. Chen, S. Oparil, P. Lucchesi, and L. J. Dell'Italia Genetic Variation in Angiotensin-Converting Enzyme Does Not Prevent Development of Cardiac Hypertrophy or Upregulation of Angiotensin II in Response to Aortocaval Fistula Circulation, February 20, 2001; 103(7): 1012 - 1016. [Abstract] [Full Text] [PDF]

				L. Tiret, C. Mallet, O. Poirier, V. Nicaud, A. Millaire, J.-B. Bouhour, G.e. Roizes, M. Desnos, R. Dorent, K. Schwartz, et al. Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: The CARDIGENE study J. Am. Coll. Cardiol., January 1, 2000; 35(1): 29 - 35. [Abstract] [Full Text] [PDF]

				B. Andersson, I. Blange, and C. Sylven Angiotensin-II type 1 receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure Eur J Heart Fail, December 17, 1999; 1(4): 363 - 369. [Abstract] [Full Text] [PDF]

				A. Okamura, M. Ohishi, H. Rakugi, T. Katsuya, Y. Yanagitani, S. Takiuchi, Y. Taniyama, K. Moriguchi, H. Ito, Y. Higashino, et al. Pharmacogenetic Analysis of the Effect of Angiotensin-Converting Enzyme Inhibitor on Restenosis After Percutaneous Transluminal Coronary Angioplasty Angiology, October 1, 1999; 50(10): 811 - 822. [Abstract] [PDF]

				M. Komajda, P. Charron, and F. Tesson Genetic aspects of heart failure Eur J Heart Fail, June 1, 1999; 1(2): 121 - 126. [Abstract] [Full Text] [PDF]

				J. A. Staessen Dr, G. Ginocchio, J. G. Wang, A. P. Saavedra, F. Soubrier, R. Vlietinck, and R. Fagard Genetic Variability in the Renin-Angiotensin System: Prevalence of Alleles and Genotypes European Journal of Cardiovascular Prevention & Rehabilitation, October 1, 1997; 4(5-6): 401 - 422. [Abstract] [PDF]